Aurinia Pharmaceuticals Inc Cash Flow Conversion Efficiency
Aurinia Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Aurinia Pharmaceuticals Inc (AUPH) has a cash flow conversion efficiency ratio of 0.085x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($52.17 Million) by net assets ($614.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aurinia Pharmaceuticals Inc (1998–2025)
Cash flow conversion efficiency of Aurinia Pharmaceuticals Inc from 1998 to 2025. This chart illustrates how Aurinia Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AUPH live share price for real-time trading data and today's change.
Aurinia Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Aurinia Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aurinia Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aurinia Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Aurinia Pharmaceuticals Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CARL ZEISS MEDITEC ADR 1
F:AFXA
|
0.008x |
|
Ningbo Huaxiang Electronic Co Ltd
SHE:002048
|
0.037x |
|
CENTRAL PUERTO ADR/1 AP1
F:C3TA
|
0.074x |
|
Tiger Brands Ltd
JSE:TBS
|
0.166x |
|
Stagwell Inc
NASDAQ:STGW
|
0.128x |
|
Cadeler As
OL:CADLR
|
0.148x |
|
Stolt-Nielsen Limited
LSE:0OHK
|
0.058x |
|
PLGO
NYSE:PLGO
|
0.122x |
Annual Cash Flow Conversion Efficiency for Aurinia Pharmaceuticals Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Aurinia Pharmaceuticals Inc from 1998 to 2025. Review Aurinia Pharmaceuticals Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $581.33 Million | $135.66 Million | 0.233x | +98.45% |
| 2024-12-31 | $377.48 Million | $44.39 Million | 0.118x | +232.82% |
| 2023-12-31 | $377.95 Million | $-33.46 Million | -0.089x | +54.87% |
| 2022-12-31 | $405.44 Million | $-79.53 Million | -0.196x | +40.40% |
| 2021-12-31 | $479.09 Million | $-157.69 Million | -0.329x | -92.12% |
| 2020-12-31 | $407.75 Million | $-69.86 Million | -0.171x | +19.54% |
| 2019-12-31 | $298.60 Million | $-63.59 Million | -0.213x | +53.55% |
| 2018-12-31 | $112.58 Million | $-51.61 Million | -0.458x | -84.57% |
| 2017-12-31 | $165.74 Million | $-41.17 Million | -0.248x | +52.28% |
| 2016-12-31 | $35.95 Million | $-18.71 Million | -0.521x | +41.51% |
| 2015-12-31 | $19.96 Million | $-17.77 Million | -0.890x | -137.47% |
| 2014-12-31 | $45.11 Million | $-16.90 Million | -0.375x | -10.20% |
| 2013-12-31 | $13.30 Million | $-4.52 Million | -0.340x | -111.01% |
| 2012-12-31 | $-2.12 Million | $-6.55 Million | 3.090x | +1561.34% |
| 2011-12-31 | $6.41 Million | $-1.36 Million | -0.211x | +69.06% |
| 2010-12-31 | $6.35 Million | $-4.34 Million | -0.683x | +68.57% |
| 2009-12-31 | $4.81 Million | $-10.46 Million | -2.175x | +1.59% |
| 2008-12-31 | $7.87 Million | $-17.39 Million | -2.210x | -120.61% |
| 2007-12-31 | $28.41 Million | $-28.46 Million | -1.002x | +3.95% |
| 2006-12-31 | $20.17 Million | $-21.03 Million | -1.043x | -108.06% |
| 2005-12-31 | $42.36 Million | $-21.23 Million | -0.501x | -29.84% |
| 2004-12-31 | $52.20 Million | $-20.15 Million | -0.386x | -415.36% |
| 2003-12-31 | $68.54 Million | $-5.13 Million | -0.075x | -319.16% |
| 2002-12-31 | $47.56 Million | $-849.90K | -0.018x | +91.30% |
| 2001-12-31 | $35.28 Million | $-7.25 Million | -0.205x | +54.55% |
| 2000-12-31 | $12.76 Million | $-5.77 Million | -0.452x | -6.20% |
| 1999-12-31 | $3.19 Million | $-1.36 Million | -0.426x | -120.49% |
| 1998-12-31 | $-846.35K | $-1.76 Million | 2.077x | -- |
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and … Read more